AP
ACAD icon

Atwood & Palmer’s Acadia Pharmaceuticals ACAD Stock Holding History

Atwood & Palmer’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-375
Closed -$12K – 396
2015
Q3 		$12K Buy
+375
New +$15.6K ﹤0.01% 313

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Atwood & Palmer's ACAD Position: Q4 2015 in Review

Atwood & Palmer sold out of Acadia Pharmaceuticals (ACAD) in Q4 2015, closing a stake of 375 shares — an estimated $12K sold.

Atwood & Palmer first reported a position in ACAD in Q3 2015 and held it in 1 quarter. The position peaked at $12K in Q3 2015. 215 funds tracked by Wall St. Rank hold ACAD as of Q4 2015.

  • Atwood & Palmer reported no remaining Acadia Pharmaceuticals position as of Q4 2015 after selling out during the quarter.
  • Atwood & Palmer sold 375 Acadia Pharmaceuticals shares in Q4 2015, an estimated $12K.
  • Atwood & Palmer first reported a position in Acadia Pharmaceuticals in Q3 2015 and held it in 1 quarter.
  • Atwood & Palmer's Acadia Pharmaceuticals position peaked at $12K in Q3 2015.
  • 215 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q4 2015.

Based on Atwood & Palmer's 13F filing for Q4 2015, filed 28 Jan 2016.